This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA to Blame for Mannkind Delay?

SAN FRANCISCO, Calif. ( TheStreet) -- Mannkind (MNKD) said late Friday that U.S. drug regulators are extending the review of its inhaled insulin device because an inspection of a third-party manufacturing facility is not yet complete.

The U.S. Food and Drug Administration was expected to issue an approval decision on the Mannkind diabetes device, now known by the brand name Afrezza, on Jan. 16. But Friday, FDA officials informed Mannkind that an inspection of a manufacturing plant owned by Organon that makes the insulin used in the Afrezza device was not complete. Organon is a subsidiary of Merck (MRK - Get Report).

Mannkind said it does not know how long the FDA's review of Afrezza will be delayed.

Mannkind investors -- both bulls and bears -- were anxiously awaiting the FDA's Jan 16 decision on Afrezza, so Friday's announcement is a bit of a letdown. Mannkind shares fell 5% to $7.60 in Friday's after-market trading session after finishing the regular session at $8.04.

The FDA delay is also somewhat of an embarrassment for Mannkind executives who have boldly predicted FDA approval of Afrezza on Jan. 16. Last week, CEO Al Mann and COO Hakan Edstrom gave separate media interviews expressing confidence that the FDA's review was essentially complete and that approval was coming.

Mannkind officials are presenting at the J.P. Morgan Healthcare Conference Tuesday. Investors will surely be asking why Mannkind didn't know that the FDA's inspection of its outside insulin supplier was not yet complete.

A person close to Mannkind told me Friday night that FDA inspectors, in fact, had already visited the Organon insulin plant, located in France, and no questions or concerns were raised, leading Mannkind to believe that the inspection was done. The company was therefore surprised Friday when FDA told them that inspectors needed to revisit the Organon plant to complete inspection on a part of the facility that was missed during the previous visit.

"The FDA messed up," said the person close to Mannkind, who asked to remain anonymous because the company doesn't want to anger the agency while the Afrezza review remains open.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRK $54.09 0.00%
MNKD $1.35 0.00%
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs